News

New COPD Inhaler Therapy Is Goal of Qualcomm-Novartis Growing Partnership

Qualcomm Incorporated recently announced that its subsidiary, Qualcomm Life, Inc., and Novartis are expanding their global partnership to advance a next generation inhaler to treat chronic obstructive pulmonary disease (COPD). Under the terms of the collaboration, Qualcomm Life is developing the reference design for the small and disposable module to power the next generation Breezhaler™, part of Novartis’…

Protein May Block COPD Bacteria Tied to Uncontrolled Inflammation

Researchers discovered that the CYLD protein turns off pathogen-induced inflammatory responses mediated by the myeloid differentiation factor 88 (MyD88), thereby preventing uncontrolled inflammation from damaging tissues and eventually inducing chronic obstructive pulmonary disease (COPD). The study, titled “Deubiquitinase CYLD acts as a negative regulator for bacterium NTHi-induced inflammation…

COPD Lung Inflammation Can Now Be Studied Using a Chip

Scientists have created a model of the human small airway using organ-on-a-chip technology that can help researchers study inflammatory lung diseases like chronic obstructive pulmonary disease (COPD) and asthma outside a patient’s body, and potentially makes it possible to more easily identify new biomarkers and evaluate drug candidates. The study, by researchers at the Harvard John A.

New Assessment Reveals that COPD Outcome in Tiotropium/olodaterol Therapy Differs According to Disease Severity

A dossier assessment developed by the German Institute for Quality and Efficiency in Health Care (IQWiG) examined the added benefit of the fixed-dose combination therapy tiotropium plus olodaterol (Spiolto Respimat), approved this year for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. The study compared tiotropium/olodaterol…